John Hoekman - Jan 26, 2022 Form 4 Insider Report for IMPEL NEUROPHARMA INC (IMPL)

Role
Chief Scientific Officer
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Stock symbol
IMPL
Transactions as of
Jan 26, 2022
Transactions value $
$0
Form type
4
Date filed
1/28/2022, 04:03 PM
Previous filing
Dec 23, 2021
Next filing
Feb 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Award $0 +35K $0.00 35K Jan 26, 2022 Common Stock 35K $9.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares on February 26, 2022 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on January 26, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.